A pharmacy sale listing is a marketing document, not a financial disclosure. It is written to generate enquiries, not to give a buyer the information needed to assess risk. Understanding what each field in a listing actually represents, and what the listing deliberately does not tell you, is the first practical skill for any prospective buyer.
This guide works through a typical listing field by field, identifies the questions each number raises rather than answers, and explains what you will need to verify before an offer makes sense. For the verification process itself, see the financial due diligence guide. For the full buying sequence from first contact to completion, see the complete buyer checklist.
What a pharmacy sale listing is really telling you
The headline asking price and turnover figure are the least useful numbers in a pharmacy listing. What matters is the NHS items dispensed per month, the income mix between NHS and non-NHS sources, and how the asking price relates to adjusted EBITDA and goodwill. None of those relationships can be verified from the listing. A listing that looks compelling on turnover may tell a very different story once the income split, the adjusted EBITDA workings, and the contract position are examined.
The anatomy of a listing, field by field
Pharmacy broker listings typically include the following fields. Each one conceals more than it reveals.
| Listing field | What it means | What it does not tell you | Verification step |
|---|---|---|---|
| NHS turnover | Reimbursement (Drug Tariff prices) and remuneration (fees and service payments) received from the NHSBSA under the Community Pharmacy Contractual Framework. Income is contract-driven and reimbursement-based, not shop takings. | The margin on that turnover; whether Category M clawbacks have been applied; and whether the figure is gross reimbursement or net of clawback adjustments. | Request 24 months of FP34 remittance advices from the NHSBSA and reconcile to accounts. |
| Total turnover | NHS turnover plus OTC retail sales, private services, and any other income lines including Pharmacy First and enhanced service payments. | The margin profile of each income line. OTC retail and private services carry a very different VAT treatment and margin from NHS dispensing. See how pharmacy VAT works. | Ask for an income split showing NHS, OTC retail and private income separately, and map the VAT treatment of each. |
| Items per month | The number of prescription items dispensed monthly under the NHS contract. This is the primary volume driver of NHS income and of goodwill value. | Whether the volume is stable, growing or declining; how concentrated it is on one or two prescribing GP surgeries; and whether it is comparable with neighbouring pharmacies or an outlier. | Request the NHSBSA dispensing data for at least 24 months. Check for trend and prescriber concentration. |
| Asking price | The seller's stated price, typically reflecting a multiple of adjusted EBITDA and an assessment of goodwill. Goodwill dominates pharmacy pricing because it is driven by the NHS contract and item volume. | The multiple used, the EBITDA figure it is applied to, or the adjustments made to arrive at that EBITDA. None of this is disclosed in the listing. | Request the seller's valuation workings. Use the purchase affordability calculator to test the price against your own EBITDA assumptions. |
| Adjusted EBITDA | Earnings before interest, tax, depreciation and amortisation, with one-off or non-recurring items removed. The seller prepares this figure. | What has been adjusted out and why. Common adjustments include owner remuneration set below market rate, non-recurring costs removed, and property charges treated inconsistently. | Request the full EBITDA bridge showing every adjustment. Rebuild the EBITDA on normalised assumptions. |
| Freehold / leasehold | Whether the property interest comes with the business. A freehold purchase includes the property asset; a leasehold purchase transfers the lease. | The lease term remaining, the rent level relative to market, the rent review mechanism, whether there are break clauses, and whether landlord consent is required for assignment. | Obtain a copy of the lease. Check unexpired term, rent review dates and any landlord alienation restrictions. |
| Staff / TUPE | An indication of the workforce. TUPE (Transfer of Undertakings, Protection of Employment) applies on a business transfer, preserving existing employees' terms and conditions. | Individual employment terms, any ongoing HR disputes, whether staff costs have been normalised in the EBITDA, or the employer NIC obligation on the inherited payroll (employer NIC is 15% above the £5,000 secondary threshold from April 2025). | Request a staff schedule with roles, hours, pay rates and length of service. Check for any settlement agreements or ongoing disputes. |
Why items per month is the number that matters most
Pharmacy income is contract-driven, not till-driven. The NHS reimburses the pharmacy for each prescription item dispensed at Drug Tariff prices and pays remuneration fees on top. Items per month is therefore the volume measure that underpins NHS dispensing income directly.
It also drives goodwill. Goodwill dominates pharmacy pricing because it is tied to the NHS contract and the dispensing volume that contract sustains. A pharmacy with a stable, high-volume NHS contract commands a different goodwill premium from one with a declining or geographically vulnerable volume, regardless of what the headline turnover says.
The items per month figure in a listing is a snapshot. Trend matters more than the single number. A pharmacy that has dispensed a consistent volume over 24 months against a spread of prescribers is a fundamentally different proposition from one whose volume is concentrated on a single GP surgery or has been declining for 18 months. The listing will not tell you which type you are looking at.
The FP34 payment cycle also means that items dispensed today generate cash roughly two months later. A high items-per-month figure implies a substantial working-capital buffer is needed from day one. The listing will not quantify this.
Adjusted EBITDA and asking price: what the listing implies and why you cannot verify it
Pharmacy valuations are typically expressed as a multiple of adjusted EBITDA, with goodwill treated as a separate component reflecting the NHS contract's value. We treat valuation as method-level only: the multiple used in any given deal is market-specific and cannot be reliably stated as a benchmark.
What a buyer needs to understand is the chain of decisions behind a listing's asking price:
- Reported EBITDA comes from the accounts. It reflects actual performance, including any owner-specific costs or choices about remuneration and property.
- Adjustments are made by the seller to normalise the figure: removing a below-market owner salary, adding back a one-off cost, or stripping out an above-market rent paid to a connected party. Each adjustment is a judgement call. The listing discloses none of them.
- Adjusted EBITDA is the result after those adjustments. It is the figure a multiple will be applied to. If the adjustments are aggressive, the adjusted EBITDA is higher than underlying performance warrants.
- Goodwill is added or the multiple implicitly captures it. The asking price is the result.
A buyer who accepts the adjusted EBITDA without rebuilding it from the accounts is accepting the seller's characterisation of what the business earns. Rebuilding it on normalised assumptions is one of the first tasks in financial due diligence. See the due diligence guide for the full workstream.
On a share purchase, there is also a corporation tax dimension: relief on goodwill is restricted for a company buyer, so the tax efficiency of the structure affects the real cost of the goodwill element of the price. See share vs asset purchase for the structuring implications.
What the listing does not tell you
These are the facts that most affect the risk and economics of a pharmacy purchase. None of them appear in a listing.
Working-capital requirement from day one
The FP34 submission cycle means prescriptions submitted this month are paid roughly two months later, with an advance on account. A buyer taking ownership mid-cycle inherits that lag. The higher the items per month, the larger the working-capital gap that needs funding from completion. The listing tells you nothing about the advance-on-account balance or how it is treated at completion.
Category M margin trend
Drug Tariff reimbursement and Category M clawbacks are set centrally and adjusted retrospectively. A listed gross margin figure reflects a point in time. Whether that margin has been contracting over the past 24 months, and by how much, is visible only in a month-by-month reconciliation of FP34 remittances to accounts. See Category M clawbacks explained for how the mechanism works.
The VAT mix
NHS prescription dispensing is zero-rated for VAT. Most OTC retail sales are standard-rated. A listing's turnover figure combines both without showing the split, which means the effective VAT position, the retail scheme in use, and the input VAT reclaim profile are all invisible. This matters for day-one cash flow and for verifying whether the current owner's VAT treatment has been correct.
Contract-transfer risk
The most significant risk a listing never mentions: the NHS pharmaceutical contract does not transfer automatically on a change of ownership. Market entry and ownership changes are regulated under the NHS (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013. Regulatory approval is required. The same applies to the GPhC premises registration. On an asset purchase the contract position is more exposed than on a share purchase, but both require careful management of the regulatory process. The buying checklist covers the notification and approval sequence in detail.
Enhanced service and Pharmacy First agreements
Pharmacy First and other enhanced service agreements are increasingly material income lines. Whether they transfer to a new owner or require re-application is not disclosed in a listing. A pharmacy with a high Pharmacy First income is a different profile from one whose total turnover is mostly dispensing volume.
The sanity-check questions to ask before you enquire
Before making a formal enquiry, a prospective buyer should be able to answer these questions, or establish why they cannot yet do so:
- What is the items-per-month figure and is it consistent over the last two years? Has the listing disclosed a trend or a snapshot?
- What proportion of NHS income comes from the top one or two prescribing GP surgeries? A listing rarely shows prescriber concentration.
- Is the EBITDA figure in the listing reported or adjusted? If adjusted, what is the adjustment narrative?
- What is the lease term remaining and what are the rent review conditions? Is landlord consent needed for assignment?
- What is the asking price relative to what the affordability calculator produces on conservative EBITDA assumptions? Use the purchase affordability calculator to stress-test the headline price before committing time to the deal.
- Is the listing for a share sale or an asset sale? The answer determines stamp duty, SDLT, TUPE mechanics, and whether the NHS contract novation is required.
- Are there any enhanced service agreements (Pharmacy First, smoking cessation, blood pressure checks) in the income, and if so are they transferable?
If a broker or seller cannot provide basic information to support these questions at the information-memorandum stage, that is itself useful data about how the process will unfold.
From listing to offer: what happens next
A listing is the beginning of a process, not the basis for a decision. The sequence after an initial enquiry typically runs through an information memorandum, management meetings, heads of terms, and then formal financial and legal due diligence before any offer is made final.
The key stages and the financial questions each raises are set out in the complete buyer checklist. The workstream for verifying the figures a listing implies is covered in the financial due diligence guide. For the buyer economics once a price is agreed, including acquisition costs, working-capital modelling and affordability, see the cost of buying a pharmacy.
The buying a pharmacy hub brings together all the relevant guides, calculators and services for prospective buyers at any stage of the process.